| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10920198 | Radiotherapy and Oncology | 2005 | 8 Pages |
Abstract
Our use of SRT for patients with primary and metastatic RCC yielded a high local control rate with low toxicity. Patients with one to three metastases, local recurrences after nephrectomy or inoperable primary tumors benefited the most, i.e. had fewer distant recurrences (13/23) and longer survival times compared to patients with >3 metastases (24/27 recurrences).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Peter J. Wersäll, Henric Blomgren, Ingmar Lax, Karl-Mikael Kälkner, Christina Linder, Göran Lundell, Bo Nilsson, Sten Nilsson, Ingemar Näslund, Pavel Pisa, Christer Svedman,